These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38685598)

  • 1. Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.
    Seufert J; Freemantle N; Guja C; Haluzík M; Tournay M; Vera C; Bonnemaire M; Kis JT
    Diabetes Obes Metab; 2024 Jul; 26(7):2988-2992. PubMed ID: 38685598
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
    Malik RA; Hwu CM; Jammah AA; Arteaga-Díaz JM; Djaballah K; Pilorget V; Alvarez A; Vera C; Vikulova O
    Diabetes Obes Metab; 2024 Jul; 26(7):2811-2819. PubMed ID: 38637981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M; Gu W; Chen L; Li Y; Kuang H; Du J; Alvarez A; Lauand F; Souhami E; Zhang J; Xu W; Du Q; Mu Y;
    Diabetes Obes Metab; 2024 Sep; 26(9):3791-3800. PubMed ID: 38922731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
    Goldman J; Trujillo JM
    Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
    Haluzík M; Al-Sofiani ME; Cheng AYY; Lauand F; Melas-Melt L; Rosenstock J
    Diabetes Obes Metab; 2024 Nov; 26(11):5046-5055. PubMed ID: 39245809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Mu Y
    Diabetes Obes Metab; 2024 Nov; 26(11):5497-5499. PubMed ID: 39157869
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
    Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
    Giorgino F; Caruso I; Napoli R
    Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
    Watada H; Takami A; Spranger R; Amano A; Hashimoto Y; Niemoeller E
    Diabetes Care; 2020 Jun; 43(6):1249-1257. PubMed ID: 32295808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
    Blonde L; Bailey TS; Chao J; Dex TA; Frias JP; Meneghini LF; Roberts M; Aroda VR
    Adv Ther; 2019 Sep; 36(9):2310-2326. PubMed ID: 31359368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
    Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
    Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
    Inoue M; Lorenz M; Muto H; Wesch R; Hashimoto Y
    Diabetes Obes Metab; 2019 Aug; 21(8):2001-2005. PubMed ID: 31050109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
    Skolnik N; Dupree RS; Johnson EL
    Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
    Davidson JA; Desouza C; Fonseca V; Frias JP; Van Gaal L; Giorgino F; Chao J; Dex TA; Roberts M; Saremi A; Leiter LA
    Diabet Med; 2020 Feb; 37(2):256-266. PubMed ID: 31365765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
    Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
    J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
    Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
    BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
    Yabe D; Iizuka K; Baxter M; Watanabe D; Kaneto H
    J Diabetes Investig; 2021 Nov; 12(11):1992-2001. PubMed ID: 33945227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
    Handelsman Y; Chovanes C; Dex T; Giorgino F; Skolnik N; Souhami E; Stager W; Niemoeller E; Frias JP
    J Diabetes Complications; 2019 Mar; 33(3):236-242. PubMed ID: 30600136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.